Skip to main content

Talquetamab-tgvs Granted Accelerated Approval for Relapsed/Refractory Multiple Myeloma

The FDA has granted accelerated approval to talquetamab-tgvs (Talvey™, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.   Why it matters: "G protein–coupled receptor, family C, group 5, member D (GPRC5D) is an orphan receptor expressed in malignant plasma cells," wrote Ajai Chari, Direct...

Continue reading

Studying the Promising Role of Bispecific Antibodies in Multiple Myeloma With Ajai Chari, MD

At the recent American Society of Hematology (ASH) Annual Meeting, Ajai Chari, MD, the Director of Research in the Multiple Myeloma Program at the Icahn School of Medicine at Mount Sinai, New York, sat down with Oncology Data Advisor to discuss his presentation regarding the phase 1/2 results of the MonumenTAL-1 study. This study researches the possible benefit of talquetamab, a bispecific antibody, in patients with relapsed or refractory multiple myeloma.  

Continue reading